Safety and immunogenicity of a Haemophilus influenzae type b conjugate vaccine in a high risk American Indian population

Pediatr Infect Dis J. 1991 Feb;10(2):113-7. doi: 10.1097/00006454-199102000-00007.


The safety and immunogenicity of a Haemophilus influenzae type b polysaccharide conjugate vaccine linked to the outer membrane protein complex of Neisseria meningitidis (Hib-OMP) were evaluated among Apache and Navajo infants and children. One dose of the Hib-OMP was given to 42 children who were from 12 and 60 months of age. Ninety-two infants 6 to 8 weeks old were given one dose of Hib-OMP at the time of enrollment. A subsequent dose of the vaccine was given 2 months later and a third dose was offered between 12 and 15 months of age. All of the 12- to 60-month-old children achieved a protective antibody concentration (greater than 1 microgram/ml) 1 month postvaccination. Among the 6- to 8-week-old infants only 11% of the Apaches and 8% of Navajos had a protective anti-PRP antibody concentration prevaccination. One month post vaccination 68% of the Apaches and 69% of the Navajos had protective anti-PRP antibody concentrations. One month after the second immunization 67% of the Apaches and 75% of Navajos had protective anti-PRP concentrations. Among the infants that received the third (booster) immunization (N = 28) 74% had protective anti-PRP antibody titers just before the booster immunization. One month after the booster immunization all of the infants had protective concentrations of anti-PRP antibody. We conclude that the Hib-OMP is safe and highly immunogenic among Apache and Navajo infants and children.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antibodies, Bacterial / analysis*
  • Arizona
  • Bacterial Outer Membrane Proteins / adverse effects
  • Bacterial Outer Membrane Proteins / immunology*
  • Bacterial Vaccines / adverse effects
  • Bacterial Vaccines / immunology*
  • Child
  • Child, Preschool
  • Haemophilus Infections / prevention & control
  • Haemophilus Vaccines*
  • Haemophilus influenzae / immunology*
  • Humans
  • Immunization Schedule
  • Indians, North American*
  • Infant
  • Polysaccharides, Bacterial / adverse effects
  • Polysaccharides, Bacterial / immunology*
  • Risk
  • Vaccination
  • Vaccines, Synthetic / adverse effects
  • Vaccines, Synthetic / immunology


  • Antibodies, Bacterial
  • Bacterial Outer Membrane Proteins
  • Bacterial Vaccines
  • Haemophilus Vaccines
  • Haemophilus influenzae-type b polysaccharide-Neisseria meningitidis outer membrane protein conjugate vaccine
  • Polysaccharides, Bacterial
  • Vaccines, Synthetic